# Rejoni

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rejoni

- Industry: Healthcare Specialists
- Headquarters: Bedford, US
- Website: www.rejoni.com
- Total disclosed funding: $65M
- Latest round: Series B (Jun 16, 2026)
- Investors on record: 8

## About

Rejoni, Inc. is a US-based company that specializes in women's reproductive health solutions, particularly aimed at preventing intrauterine adhesions through innovative medical products.Founded in 2020 and headquartered in Bedford, US, Rejoni, Inc. focuses on developing medical technologies to improve women's reproductive health. The company has completed four deals as of October 2023, with its latest funding round being a Series B raising USD 0.250 mn. The current company valuation stands at USD 112.854 mn.Rejoni™ specializes in developing innovative solutions for women's reproductive health, focusing on preventing intrauterine adhesions, commonly known as Asherman's Syndrome, which can arise following uterine procedures. Their primary product, Juveena™ Hydrogel, is designed to be instilled into the uterus immediately after surgical interventions such as fibroid removal or adhesiolysis, with the intent of minimizing scar tissue formation. By addressing the critical issue of intrauterine adhesions, Rejoni aims to improve women’s health outcomes by reducing associated complications such as menstrual irregularities and pregnancy losses. The clinical trials for Juveena™ Hydrogel target potential participants in the United States undergoing relevant surgical procedures, leveraging partnerships with leading physicians to expand its reach and efficacy in women's healthcare markets.Rejoni™ operates on a revenue model primarily driven by clinical trial partnerships and the eventual commercialization of its flagship product, Juveena™ Hydrogel. The company engages with healthcare providers and clinical institutions to facilitate its research initiatives, which may involve service contracts or collaborations that allow for the testing and evaluation of the hydrogel in clinical settings. Revenue generation is anticipated to grow as Juveena™ Hydrogel progresses through the trial phases and moves toward regulatory approval, leading to potential direct sales to medical facilities and practitioners. The business structure emphasizes B2B relationships, focusing on partnerships with healthcare providers who will administer the product and potentially incorporate it into their surgical protocols once it receives market authorization. In June 2026, Rejoni, Inc. raised USD 25 million in venture funding from ClavystBio, with participation from AMED Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital Partners, and Sparta Group. The company will use the funding to scale manufacturing and supply, build market access and engagement, and prepare for regulatory approval and launch of its hydrogel system.

## Funding rounds

- Series B, Jun 16, 2026, $25M — Catalyst Health Ventures, Ascension Ventures, Sparta Group, Delos Capital, AMED Ventures, FemHealth Ventures, Iyengar Capital Partners, ClavystBio
- Series B, Dec 7, 2022, $25M — Catalyst Health Ventures, Ascension Ventures, Sparta Group, Delos Capital, AMED Ventures, Iyengar Capital Partners
- Series A, Sep 4, 2020, $15M — Ascension Ventures, Delos Capital, Sparta Group

## Investors

- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series A, Series B
- Delos Capital (https://capitalatlas.ai/funds/delos-capital) — Series A, Series B
- Sparta Group — Series A, Series B
- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series B
- AMED Ventures (https://capitalatlas.ai/funds/amed-ventures) — Series B
- Iyengar Capital Partners (https://capitalatlas.ai/funds/iyengar-capital-partners) — Series B
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Series B
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Series B